Newsfeeds - Spark Newswire

2 minute read

News

Kazia Therapeutics Announced EVT801 Phase I Study Receives Full Regulatory Approval in France

Today, 5:32 AM

Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to inform stakeholders that the planned phase I study for EVT801 has received full approval from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French regulatory agency.

KZIA

2 minute read

News

Kazia Therapeutics Announced Manufacturing Patents Granted for Paxalisib in Key Territories; Extend Effective Patent Protection to 2036

By Charles Gross

Today, 5:32 AM

Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce the grant of patents by the respective agencies of the United States and India in respect of the manufacturing process for paxalisib. A similar patent has been accepted in Australia and is expected to proceed to grant in 3Q CY2021.

KZIA

2 minute read

Uncategorized

Kazia Therapeutics Shares See Volume; Edison Investment Research Publishes PR Titled ‘New asset to target tumor lymphangiogenesis’

By Benzinga Newsdesk

Today, 5:32 AM

Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule

KZIA

Latest news

Kazia Therapeutics Announced EVT801 Phase I Study Receives Full Regulatory Approval in France

Kazia Therapeutics Announced Manufacturing Patents Granted for Paxalisib in Key Territories; Extend Effective Patent Protection to 2036

Kazia Therapeutics Shares See Volume; Edison Investment Research Publishes PR Titled ‘New asset to target tumor lymphangiogenesis’